Janus Henderson Group PLC Has $217.95 Million Stock Holdings in PRA Health Sciences Inc (NASDAQ:PRAH)

Janus Henderson Group PLC increased its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 11.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,960,897 shares of the medical research company’s stock after acquiring an additional 200,498 shares during the period. Janus Henderson Group PLC’s holdings in PRA Health Sciences were worth $217,954,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in PRAH. Massachusetts Financial Services Co. MA raised its holdings in PRA Health Sciences by 174.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,705,678 shares of the medical research company’s stock valued at $189,586,000 after buying an additional 1,083,837 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in PRA Health Sciences by 27,132.6% during the third quarter. Point72 Asset Management L.P. now owns 1,002,978 shares of the medical research company’s stock valued at $99,526,000 after purchasing an additional 999,295 shares during the last quarter. Redmile Group LLC bought a new position in shares of PRA Health Sciences in the third quarter valued at approximately $39,236,000. Millennium Management LLC raised its position in shares of PRA Health Sciences by 66.4% in the third quarter. Millennium Management LLC now owns 760,496 shares of the medical research company’s stock valued at $75,464,000 after purchasing an additional 303,514 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of PRA Health Sciences in the fourth quarter worth $18,731,000. Institutional investors and hedge funds own 99.60% of the company’s stock.

Several research firms recently issued reports on PRAH. Goldman Sachs Group downgraded shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $130.00 to $120.00 in a report on Friday, January 10th. Jefferies Financial Group dropped their target price on shares of PRA Health Sciences from $125.00 to $89.00 and set a “buy” rating on the stock in a report on Monday. Robert W. Baird boosted their target price on shares of PRA Health Sciences from $122.00 to $128.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. SunTrust Banks decreased their price target on shares of PRA Health Sciences from $127.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Finally, Citigroup initiated coverage on PRA Health Sciences in a research report on Monday, January 6th. They issued a “neutral” rating and a $120.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $111.44.

NASDAQ PRAH opened at $74.19 on Thursday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.97 and a current ratio of 0.97. The firm has a 50-day simple moving average of $95.43 and a 200 day simple moving average of $101.65. PRA Health Sciences Inc has a twelve month low of $58.67 and a twelve month high of $113.10. The stock has a market cap of $4.55 billion, a PE ratio of 20.11 and a beta of 1.11.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Thursday, February 20th. The medical research company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.32 by $0.22. PRA Health Sciences had a return on equity of 28.52% and a net margin of 7.93%. The firm had revenue of $800.24 million during the quarter, compared to analysts’ expectations of $794.91 million. During the same quarter in the prior year, the firm posted $1.31 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. Research analysts forecast that PRA Health Sciences Inc will post 4.8 earnings per share for the current fiscal year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: What can cause a stock to outperform?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.